PRMT5 inhibitors for cancer, sickle cell, and HPFH treatment

ChangeBridge: Patent Grants - Organic Chemistry (C07D)

Published April 7th, 2026

Detected April 7th, 2026

Summary

USPTO granted patent US12595262B2 to Merck Sharp & Dohme LLC for PRMT5 inhibitor compounds and methods of treatment for cancer, sickle cell disease, and hereditary persistence of foetal hemoglobin (HPFH). The patent covers 14 claims including compounds A through D and their pharmaceutical salts, esters, and prodrugs.

View original document View source feed page

What changed

USPTO issued patent US12595262B2 to Merck Sharp & Dohme LLC covering PRMT5 (protein arginine methyltransferase 5) inhibitor compounds and their use in treating cancer, sickle cell disease, and hereditary persistence of foetal hemoglobin. The patent includes 14 claims directed to the compounds themselves, pharmaceutical compositions, and methods of treatment.\n\nFor pharmaceutical companies developing oncology or hematology treatments targeting PRMT5, this patent may impact freedom-to-operate considerations. Competitors researching similar PRMT5 inhibitor mechanisms should assess potential infringement risks. The patent does not impose regulatory compliance obligations but establishes proprietary rights that could affect competitive R&D strategies in this therapeutic area.

What to do next

Review patent claims for freedom-to-operate analysis
Monitor for related patent applications in therapeutic space
Evaluate licensing opportunities if applicable

Source document (simplified)

← USPTO Patent Grants

PRMT5 inhibitors

Grant US12595262B2 Kind: B2 Apr 07, 2026

Assignee

Merck Sharp & Dohme LLC

Inventors

Michelle Machacek, Michael D. Altman, Chunhui Huang, Michael H. Reutershan, David L. Sloman, David J. Witter, Craig R. Gibeau

Abstract

The present invention provides a compound selected from: compounds A, B, C, D and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds disclosed herein, pharmaceutical compositions comprising compounds disclosed herein, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.